DDInter948 DDInter1848
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.
Trastuzumab emtansine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amprenavir
Trastuzumab emtansine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Trastuzumab emtansine {u} may lead to a major life threatening interaction when taken with {v} Ticlopidine
Trastuzumab emtansine {u} may lead to a major life threatening interaction when taken with {v} Apixaban
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Ticlopidine
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Apixaban